New Risk • Apr 25
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 22% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (7.4% net profit margin). Announcement • Mar 30
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd to Report Q1, 2026 Results on Apr 25, 2026 Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd announced that they will report Q1, 2026 results on Apr 25, 2026 Reported Earnings • Mar 30
Full year 2025 earnings released: EPS: CN¥0.11 (vs CN¥0.11 in FY 2024) Full year 2025 results: EPS: CN¥0.11 (down from CN¥0.11 in FY 2024). Revenue: CN¥388.3m (flat on FY 2024). Net income: CN¥40.7m (down 1.9% from FY 2024). Profit margin: 11% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth. Announcement • Mar 28
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd, Annual General Meeting, Apr 17, 2026 Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd, Annual General Meeting, Apr 17, 2026, at 12:00 China Standard Time. Location: The Company's Meeting Room, Urumqi, Xinjiang China New Risk • Jan 13
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Jan 08
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to CN¥9.92, the stock trades at a trailing P/E ratio of 76x. Average trailing P/E is 33x in the Pharmaceuticals industry in China. Total returns to shareholders of 59% over the past three years. Announcement • Dec 26
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd to Report Fiscal Year 2025 Results on Mar 28, 2026 Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd announced that they will report fiscal year 2025 results on Mar 28, 2026 Valuation Update With 7 Day Price Move • Nov 24
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥9.06, the stock trades at a trailing P/E ratio of 69.4x. Average trailing P/E is 34x in the Pharmaceuticals industry in China. Total returns to shareholders of 33% over the past three years. Reported Earnings • Oct 28
Third quarter 2025 earnings released: EPS: CN¥0.019 (vs CN¥0.003 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.019 (up from CN¥0.003 in 3Q 2024). Revenue: CN¥96.5m (up 2.3% from 3Q 2024). Net income: CN¥7.19m (up 457% from 3Q 2024). Profit margin: 7.5% (up from 1.4% in 3Q 2024). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. New Risk • Oct 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Announcement • Sep 30
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd to Report Q3, 2025 Results on Oct 28, 2025 Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd announced that they will report Q3, 2025 results on Oct 28, 2025 New Risk • Aug 25
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 25% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company. Announcement • Jun 30
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd to Report First Half, 2025 Results on Aug 22, 2025 Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd announced that they will report first half, 2025 results on Aug 22, 2025 Reported Earnings • Apr 28
First quarter 2025 earnings released: EPS: CN¥0.054 (vs CN¥0.054 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.054 (in line with 1Q 2024). Revenue: CN¥96.9m (up 6.6% from 1Q 2024). Net income: CN¥20.7m (flat on 1Q 2024). Profit margin: 21% (down from 23% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Apr 01
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to CN¥7.80, the stock trades at a trailing P/E ratio of 72.2x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Total loss to shareholders of 14% over the past three years. Announcement • Mar 28
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd to Report Q1, 2025 Results on Apr 26, 2025 Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd announced that they will report Q1, 2025 results on Apr 26, 2025 Reported Earnings • Mar 12
Full year 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.034 in FY 2023) Full year 2024 results: EPS: CN¥0.11 (up from CN¥0.034 in FY 2023). Revenue: CN¥385.8m (up 4.5% from FY 2023). Net income: CN¥41.5m (up 220% from FY 2023). Profit margin: 11% (up from 3.5% in FY 2023). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Announcement • Mar 12
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd, Annual General Meeting, Apr 02, 2025 Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd, Annual General Meeting, Apr 02, 2025, at 12:00 China Standard Time. Location: The Company's Meeting Room, Urumqi, Xinjiang China Announcement • Dec 27
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd to Report Fiscal Year 2024 Results on Mar 12, 2025 Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd announced that they will report fiscal year 2024 results on Mar 12, 2025 Announcement • Dec 19
Mi Zaiqi, Mi Enhua and Yang Xiaoling completed the acquisition of 20.71% stake in Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd (SHSE:600721) from Xinjiang Hualing Industry and Trade (Group) CO., Ltd. Mi Zaiqi, Mi Enhua and Yang Xiaoling agreed to acquire 20.71% stake in Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd (SHSE:600721) from Xinjiang Hualing Industry and Trade (Group) CO., Ltd on December 2, 2024.
Mi Zaiqi, Mi Enhua and Yang Xiaoling completed the acquisition of 20.71% stake in Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd (SHSE:600721) from Xinjiang Hualing Industry and Trade (Group) CO., Ltd on December 16, 2024. Reported Earnings • Oct 28
Third quarter 2024 earnings released: EPS: CN¥0.003 (vs CN¥0.012 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.003 (down from CN¥0.012 in 3Q 2023). Revenue: CN¥94.3m (down 4.2% from 3Q 2023). Net income: CN¥1.29m (down 73% from 3Q 2023). Profit margin: 1.4% (down from 4.8% in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Announcement • Sep 30
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd to Report Q3, 2024 Results on Oct 25, 2024 Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd announced that they will report Q3, 2024 results on Oct 25, 2024 Reported Earnings • Aug 21
Second quarter 2024 earnings released: EPS: CN¥0.005 (vs CN¥0.017 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.005 (down from CN¥0.017 in 2Q 2023). Revenue: CN¥105.4m (up 15% from 2Q 2023). Net income: CN¥2.00m (down 68% from 2Q 2023). Profit margin: 1.9% (down from 6.9% in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. New Risk • Jul 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Announcement • Jun 29
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd to Report First Half, 2024 Results on Aug 21, 2024 Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd announced that they will report first half, 2024 results on Aug 21, 2024 Reported Earnings • Apr 27
First quarter 2024 earnings released: EPS: CN¥0.054 (vs CN¥0.018 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.054 (up from CN¥0.018 in 1Q 2023). Revenue: CN¥90.9m (up 20% from 1Q 2023). Net income: CN¥20.7m (up 209% from 1Q 2023). Profit margin: 23% (up from 8.8% in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Announcement • Apr 27
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd, Annual General Meeting, May 20, 2024 Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd, Annual General Meeting, May 20, 2024, at 12:00 China Standard Time. Location: The Company's Meeting Room, Urumqi, Xinjiang China Announcement • Mar 30
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd to Report Q1, 2024 Results on Apr 26, 2024 Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd announced that they will report Q1, 2024 results on Apr 26, 2024 Announcement • Dec 29
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd to Report Fiscal Year 2023 Results on Apr 26, 2024 Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd announced that they will report fiscal year 2023 results on Apr 26, 2024 Announcement • Sep 30
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd to Report Q3, 2023 Results on Oct 27, 2023 Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd announced that they will report Q3, 2023 results on Oct 27, 2023 Reported Earnings • Aug 31
Second quarter 2023 earnings released: EPS: CN¥0.017 (vs CN¥0.023 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.017 (down from CN¥0.023 in 2Q 2022). Revenue: CN¥91.5m (down 13% from 2Q 2022). Net income: CN¥6.31m (down 29% from 2Q 2022). Profit margin: 6.9% (down from 8.5% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 12
Full year 2022 earnings released: CN¥0.092 loss per share (vs CN¥0.16 profit in FY 2021) Full year 2022 results: CN¥0.092 loss per share (down from CN¥0.16 profit in FY 2021). Revenue: CN¥349.9m (up 24% from FY 2021). Net loss: CN¥34.8m (down 158% from profit in FY 2021). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Jinsong Wang was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 29
Second quarter 2022 earnings released: EPS: CN¥0.023 (vs CN¥0.13 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.023 (down from CN¥0.13 in 2Q 2021). Revenue: CN¥105.0m (up 45% from 2Q 2021). Net income: CN¥8.92m (down 82% from 2Q 2021). Profit margin: 8.5% (down from 67% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • May 30
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥8.10, the stock trades at a trailing P/E ratio of 50.5x. Average trailing P/E is 26x in the Metals and Mining industry in China. Total returns to shareholders of 59% over the past three years. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 4 independent directors (7 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Mar 31
Full year 2021 earnings released: EPS: CN¥0.16 (vs CN¥0.82 loss in FY 2020) Full year 2021 results: EPS: CN¥0.16 (up from CN¥0.82 loss in FY 2020). Revenue: CN¥281.4m (up 233% from FY 2020). Net income: CN¥59.8m (up CN¥379.6m from FY 2020). Profit margin: 21% (up from net loss in FY 2020). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Reported Earnings • Oct 27
Third quarter 2021 earnings released: EPS CN¥0.013 (vs CN¥0.013 loss in 3Q 2020) The company reported a soft third quarter result with weaker revenues and profit margins, although earnings were improved. Third quarter 2021 results: Revenue: CN¥64.6m (down 471% from 3Q 2020). Net income: CN¥4.95m (up CN¥10.1m from 3Q 2020). Profit margin: 7.7% (down from 30% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 18
Second quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.098 loss in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥72.5m (up 12% from 2Q 2020). Net income: CN¥48.9m (up CN¥88.4m from 2Q 2020). Profit margin: 67% (up from net loss in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 24
First quarter 2021 earnings released: EPS CN¥0.003 (vs CN¥0.007 in 1Q 2020) The company reported a mediocre first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: CN¥47.3m (up 38% from 1Q 2020). Net income: CN¥1.07m (down 62% from 1Q 2020). Profit margin: 2.3% (down from 8.3% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 01
Full year 2020 earnings released: CN¥0.82 loss per share (vs CN¥0.086 profit in FY 2019) The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: CN¥84.5m (down 68% from FY 2019). Net loss: CN¥319.8m (down CN¥354.2m from profit in FY 2019). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings. Announcement • Mar 09
Xinjiang Baihuacun Co., Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021 Xinjiang Baihuacun Co., Ltd. announced that they will report fiscal year 2020 results on Mar 31, 2021 Is New 90 Day High Low • Jan 28
New 90-day low: CN¥3.33 The company is down 26% from its price of CN¥4.48 on 30 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Metals and Mining industry, which is up 19% over the same period. Is New 90 Day High Low • Jan 07
New 90-day low: CN¥3.68 The company is down 25% from its price of CN¥4.88 on 09 October 2020. The Chinese market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Metals and Mining industry, which is up 21% over the same period. Is New 90 Day High Low • Dec 08
New 90-day low: CN¥4.02 The company is down 18% from its price of CN¥4.91 on 09 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Metals and Mining industry, which is up 6.0% over the same period. Is New 90 Day High Low • Oct 24
New 90-day low: CN¥4.66 The company is down 9.0% from its price of CN¥5.13 on 24 July 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Metals and Mining industry, which is down 3.0% over the same period. Reported Earnings • Oct 23
Third quarter earnings released Over the last 12 months the company has reported total losses of CN¥57.3m, with losses narrowing by 92% from the prior year. Total revenue was CN¥141.3m over the last 12 months, down 46% from the prior year. Announcement • Oct 19
Xinjiang Baihuacun Co., Ltd. to Report Q3, 2020 Results on Oct 23, 2020 Xinjiang Baihuacun Co., Ltd. announced that they will report Q3, 2020 results on Oct 23, 2020 Announcement • Sep 30
Xinjiang Baihuacun Co., Ltd. announced that it expects to receive CNY 429.904 million in funding from Xinjiang Hualing International Medical Industry Development Co., Ltd, Guangxi Jinlan Investment Management Center (Limited Partnership), Fusi Asset Management (Beijing) Co., Ltd Xinjiang Baihuacun Co., Ltd. (SHSE:600721) announced a private placement of A shares for a price of CNY 3.82 per share for a gross proceeds of not more than CNY 429,904,000 on June 8, 2020. The transaction involve participation from 35 specific investors including the company’s controlling shareholder, wholly-owned subsidiary Xinjiang Hualing International Medical Industry Development Co., Ltd. subscribing for not more than 64,260,500 shares for an amount not exceeding CNY 245,475,200, Guangxi Jinlan Investment Management Center (Limited Partnership) subscribing for not more than 24,139,900 shares for an amount not exceeding CNY 92,214,400 and Fusi Asset Management (Beijing) Co., Ltd subscribing for not more than 24,139,900 shares for an amount not exceeding CNY 92,214,400. The company will adjust the offer price if the company's stocks have dividends, dividends, capital accumulation funds converted into share capital and other ex-rights and ex-dividends during the period. The final number of shares will be determine by the company’s board of directors in accordance with the authorization of the general meeting of shareholders after obtaining the approval of the China Securities Regulatory Commission. The shares are non-transferable for 18 months from the date of issuance. The share will be trade on stock exchange after the completion of lock-up period. The validity period of the issuance is 12 months from the date of approval. The transaction was approved by its board in the 10th meeting of the 7th supervisory committee and is subject to approval of shareholders at the 2nd special shareholders' Meeting of 2020 to be held on June 24, 2020 and China Securities Regulatory Commission.. Announcement • Jul 08
Xinjiang Baihuacun Co., Ltd. to Report First Half, 2020 Results on Aug 20, 2020 Xinjiang Baihuacun Co., Ltd. announced that they will report first half, 2020 results on Aug 20, 2020